CMPX icon

Compass Therapeutics

3.56 USD
-0.09
2.47%
Updated Feb 12, 11:41 AM EST
1 day
-2.47%
5 days
2.01%
1 month
82.56%
3 months
98.88%
6 months
215.04%
Year to date
154.29%
1 year
119.75%
5 years
-10.55%
10 years
-10.55%
 

About: Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.

Employees: 32

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

81% more capital invested

Capital invested by funds: $93.6M [Q2] → $170M (+$76.1M) [Q3]

47% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 19

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0.61% less ownership

Funds ownership: 67.65% [Q2] → 67.03% (-0.61%) [Q3]

4% less funds holding

Funds holding: 82 [Q2] → 79 (-3) [Q3]

14% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 14

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$8
125%
upside
Avg. target
$16.67
368%
upside
High target
$32
799%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Jefferies
Maury Raycroft
9% 1-year accuracy
1 / 11 met price target
125%upside
$8
Buy
Maintained
10 Feb 2025
HC Wainwright & Co.
Joseph Pantginis
25% 1-year accuracy
102 / 413 met price target
181%upside
$10
Buy
Reiterated
10 Jan 2025
D. Boral Capital
Jason Kolbert
35% 1-year accuracy
76 / 217 met price target
799%upside
$32
Buy
Maintained
8 Jan 2025

Financial journalist opinion

Based on 3 articles about CMPX published over the past 30 days

Positive
Zacks Investment Research
1 day ago
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock?
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock?
Positive
MarketBeat
1 week ago
Top 3 High-Momentum Companies Analysts Are Still Bullish On
The principle of momentum investing—though contrary to the traditional wisdom of buying low and selling high—suggests that investors can profit by buying rising stocks and selling them before they decline. As a result, momentum is typically favored in short-term and active trading strategies rather than long-term investing.
Top 3 High-Momentum Companies Analysts Are Still Bullish On
Positive
Zacks Investment Research
1 week ago
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why
CMPX stock more than doubles following updates regarding the pipeline development programs and current cash position by the company.
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why
Positive
Zacks Investment Research
2 months ago
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year?
Here is how Compass Therapeutics, Inc. (CMPX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year?
Neutral
GlobeNewsWire
2 months ago
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor.
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
Neutral
Seeking Alpha
2 months ago
Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer
Compass Therapeutics' CTX-009 shows promise in biliary tract cancer, with a 37.5% response rate in phase 2 trials and a pivotal phase 2/3 readout expected in Q1 2025. Financially, CMPX is stable with $36.8 million in cash and $98.6 million in marketable securities, ensuring a runway through 2025 without major cash concerns. Risks include the non-standard comparator in the pivotal trial and the historically low success rate of novel anti-angiogenic therapies in solid tumors.
Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer
Neutral
GlobeNewsWire
2 months ago
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Piper Sandler 36th Annual Healthcare Conference taking place in New York City, NY December 3-5, 2024.
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Positive
Zacks Investment Research
2 months ago
Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. (CMPX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX)
Positive
Zacks Investment Research
2 months ago
What Makes Compass Therapeutics, Inc. (CMPX) a New Buy Stock
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Compass Therapeutics, Inc. (CMPX) a New Buy Stock
Neutral
GlobeNewsWire
2 months ago
Compass Therapeutics to Participate in Upcoming Investor Events
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November 2024.
Compass Therapeutics to Participate in Upcoming Investor Events
Charts implemented using Lightweight Charts™